drugset / Trial / NCT00004288

Phase II Pilot Study of Olsalazine for Ankylosing Spondylitis

NCT00004288

Treatment

Summary

OBJECTIVES: I. Assess the safety and efficacy of olsalazine, a dimer of 5-aminosalicylic acid, in men with ankylosing spondylitis unresponsive to nonsteroidal anti-inflammatory drugs and physiotherapy.

Timeline

Start
1996-05
Primary completion
Completion
1999-12

Drugs

EvaluationDrugModalityDoseRoute
Subject olsalazine Small molecule